Exercise programs with higher intensity levels result in better outcomes for patients
the ONA take:
A supervised, moderate- to high-intensity exercise program that combines resistance and aerobic exercise (eg, OnTrack) is most effective for patients with breast cancer undergoing adjuvant chemotherapy.
However, a home-based, low-intensity physical activity program (eg, Onco-Move) provides some benefit and is a viable alternative for women who cannot or will not participate in more intensive exercise compared with usual care (UC).
In this study, 230 women who were scheduled to undergo adjuvant chemotherapy were randomly assigned to Onco-Move, OnTrack, or (UC). Assessments were made before assignment, at the end of chemotherapy, and at the 6-month follow-up.
Cardiorespiratory fitness, physical functioning, nausea and vomiting, and pain outcomes were all better in the intervention groups compared with the UC group.
Those in the OnTrack group also had better muscle strength and less physical fatigue, plus a smaller percentage of them needed dose adjustments.
In addition, patients in both intervention groups returned earlier, as well as for more hours per week, to work than patients in the UC group.
A supervised, moderate- to high-intensity exercise program is most effective for patients with breast cancer undergoing adjuvant chemotherapy.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|